We have shown that the latest generation of archaeal vaccine adjuvants, the synthetic SLA liposome admixed with antigen synergizes with anti-PD-1 and anti-CTLA-4 therapy to induce CD8+ T cells in the tumor and enhances protection from tumor development to a similar extent than the traditionally formulated MS liposomes with encapsulated antigen. The gene discussed is CD8A; the disease is neoplasm.